FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002539807> ?p ?o ?g. }

• W2002539807 endingPage "315" @default.
• W2002539807 startingPage "309" @default.
• W2002539807 abstract "The effects of ethane hydroxy diphosphonate (EHDP) on quantitative bone histology have been studied in 43 pagetic patients treated for 6 months at a dose of 5 mg/kg/day. To determine the therapeutic effects on pagetic bone and to appreciate the side effects in non-pagetic bone, the patients were biopsied either in pagetic or non-pagetic areas of the ilium before the beginning of the treatment and at 3, 6 and 9 months (i.e. 3 months post-therapy) after the inception of treatment. Tetracycline double labelling of bone was performed before biopsies in each patient to measure the calcification rate. The results demonstrate that 5 mg/kg/day EHDP given for 6 months has a marked antiosteoclastic effect which is prolonged after the cessation of treatment. Pagetic osteoclasts appear more sensitive to EHDP than normal osteoclasts. The new bone formed during treatment has a regular lamellar texture. At the same time, the high appositional rate of pagetic bone is reduced to a normal value. Marrow fibrosis is reduced along with the reduction in the osteoclast population. Thus, pagetic bone changes to bone normal in quantity, quality and metabolism. Dynamically, in nonpagetic areas, a transitory decrease of calcification rate Is noted at the end of the treatment, without morphological evidence of osteomalacia, except for 2 out of 43 cases. Histologically, EHDP given at a dose of 5 mg/kg/day for 6 months appears to be an effective and safe treatment for Paget's disease of bone. Les effets de l'éthane-1-hydroxy-1, 1-diphosphonate (EHDP) sur lea param`etres histologiques osseux quantitatifs ont étéétudiés chez 43 pagétiques traités pendant 6 moss par 5 mg/kg/jour d'EHDP. Afin de déterminer lea effets thérapeutiques sur l'os pagétique et d'éventuels effets secondaires our l'os non pagétique, les malades ont tous subi deux biopsies transiliaques, l'une avant le debut du traitement, l'autre 3, 6 ou 9 mols plus tard (soit, dons ce dernler cas, 3 mols après l'arrêt du traitement). Les prélèvements ont port́e soit en territolre pagétique, soit sur i'os non pagétique, et ont été effectués après double marquage par la tétracycline, qui permet la mesure de la vitesse de calcification. que celu!-c! se poursuit au-delà de l'arrêt du traltement. Les ostéoclastes pagétiques semblent plus sensibles à l'EHDP qua les ostéociastes normaux. L'os nouveau formé sous traitement a une texture lameflaire régulière, on même temps qua la vitesse d'apposition en os pagdtique est ramenée à la normale. La fibrose médullaire diminue avec la population ostéoclastique. Donc I'os pagdtique tend à devenir normal de par sa quantité, sa qualité et son métabolisms. Dynamiquement, on note en os non pagétique une réduction trensitoire de la vitesse de calcification on fin de traitement, mais sans signe morphologique d'ostéomalacle, sauf dons 2 cas sur 43. D'un point de vue histologique, l'EHDP, prescrit à la dose de 5 mg/kg/jour pendant 6 mois, apparaft comme un traltement efficace et sans danger de is maladie osseuse de Paget." @default.
• W2002539807 created "2016-06-24" @default.
• W2002539807 creator A5023257490 @default.
• W2002539807 creator A5056941150 @default.
• W2002539807 creator A5059478181 @default.
• W2002539807 creator A5068477084 @default.
• W2002539807 creator A5068648941 @default.
• W2002539807 date "1981-01-01" @default.
• W2002539807 modified "2023-09-26" @default.
• W2002539807 title "Effects of ethane-1 hydroxy-1, 1-Diphosphonate (5 mg/kg/day dose) onquantitative bone histology in paget's disease of bone" @default.
• W2002539807 cites W1963935558 @default.
• W2002539807 cites W1967341298 @default.
• W2002539807 cites W1971712306 @default.
• W2002539807 cites W1976850617 @default.
• W2002539807 cites W1995556654 @default.
• W2002539807 cites W2010226556 @default.
• W2002539807 cites W2042353520 @default.
• W2002539807 cites W2045747724 @default.
• W2002539807 cites W2047495527 @default.
• W2002539807 cites W2048681811 @default.
• W2002539807 cites W2054083060 @default.
• W2002539807 cites W2064228165 @default.
• W2002539807 cites W2073963206 @default.
• W2002539807 cites W2074138272 @default.
• W2002539807 cites W2089566066 @default.
• W2002539807 cites W2171293061 @default.
• W2002539807 cites W2337075852 @default.
• W2002539807 cites W4323254177 @default.
• W2002539807 doi "https://doi.org/10.1016/0221-8747(81)90047-3" @default.
• W2002539807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6820112" @default.
• W2002539807 hasPublicationYear "1981" @default.
• W2002539807 type Work @default.
• W2002539807 sameAs 2002539807 @default.
• W2002539807 citedByCount "48" @default.
• W2002539807 countsByYear W20025398072020 @default.
• W2002539807 crossrefType "journal-article" @default.
• W2002539807 hasAuthorship W2002539807A5023257490 @default.
• W2002539807 hasAuthorship W2002539807A5056941150 @default.
• W2002539807 hasAuthorship W2002539807A5059478181 @default.
• W2002539807 hasAuthorship W2002539807A5068477084 @default.
• W2002539807 hasAuthorship W2002539807A5068648941 @default.
• W2002539807 hasConcept C126322002 @default.
• W2002539807 hasConcept C142724271 @default.
• W2002539807 hasConcept C170033053 @default.
• W2002539807 hasConcept C170493617 @default.
• W2002539807 hasConcept C2776033226 @default.
• W2002539807 hasConcept C2776154862 @default.
• W2002539807 hasConcept C2776169692 @default.
• W2002539807 hasConcept C2776541429 @default.
• W2002539807 hasConcept C2778049618 @default.
• W2002539807 hasConcept C2779134260 @default.
• W2002539807 hasConcept C2780309369 @default.
• W2002539807 hasConcept C2908647359 @default.
• W2002539807 hasConcept C57742111 @default.
• W2002539807 hasConcept C71924100 @default.
• W2002539807 hasConcept C81880429 @default.
• W2002539807 hasConcept C99454951 @default.
• W2002539807 hasConceptScore W2002539807C126322002 @default.
• W2002539807 hasConceptScore W2002539807C142724271 @default.
• W2002539807 hasConceptScore W2002539807C170033053 @default.
• W2002539807 hasConceptScore W2002539807C170493617 @default.
• W2002539807 hasConceptScore W2002539807C2776033226 @default.
• W2002539807 hasConceptScore W2002539807C2776154862 @default.
• W2002539807 hasConceptScore W2002539807C2776169692 @default.
• W2002539807 hasConceptScore W2002539807C2776541429 @default.
• W2002539807 hasConceptScore W2002539807C2778049618 @default.
• W2002539807 hasConceptScore W2002539807C2779134260 @default.
• W2002539807 hasConceptScore W2002539807C2780309369 @default.
• W2002539807 hasConceptScore W2002539807C2908647359 @default.
• W2002539807 hasConceptScore W2002539807C57742111 @default.
• W2002539807 hasConceptScore W2002539807C71924100 @default.
• W2002539807 hasConceptScore W2002539807C81880429 @default.
• W2002539807 hasConceptScore W2002539807C99454951 @default.
• W2002539807 hasIssue "4-5" @default.
• W2002539807 hasLocation W20025398071 @default.
• W2002539807 hasLocation W20025398072 @default.
• W2002539807 hasOpenAccess W2002539807 @default.
• W2002539807 hasPrimaryLocation W20025398071 @default.
• W2002539807 hasRelatedWork W1981487916 @default.
• W2002539807 hasRelatedWork W1989006435 @default.
• W2002539807 hasRelatedWork W2002539807 @default.
• W2002539807 hasRelatedWork W2039760050 @default.
• W2002539807 hasRelatedWork W2063318740 @default.
• W2002539807 hasRelatedWork W2068836076 @default.
• W2002539807 hasRelatedWork W2131542318 @default.
• W2002539807 hasRelatedWork W2397934643 @default.
• W2002539807 hasRelatedWork W2418946816 @default.
• W2002539807 hasRelatedWork W3022593995 @default.
• W2002539807 hasVolume "3" @default.
• W2002539807 isParatext "false" @default.
• W2002539807 isRetracted "false" @default.
• W2002539807 magId "2002539807" @default.
• W2002539807 workType "article" @default.